公开(公告)号：US07482463B2

公开(公告)日：2009-01-27

申请号：US11946193

申请日：2007-11-28

Applicant: Mahavir Singh Khanna ,  Bakthavathsalan Vijayaraghavan ,  Mohan Prasad ,  Yatendra Kumar

Inventor： Mahavir Singh Khanna ,  Bakthavathsalan Vijayaraghavan ,  Mohan Prasad ,  Yatendra Kumar

IPC: C07D401/12

CPC classification number: C07D401/12

Abstract: The invention relates to an amorphous form of the salts of the (-) enantiomer or (S)-enantiomer of omeprazole, i.e., esomeprazole. The invention also relates to processes for preparing amorphous esomeprazole salts and pharmaceutical compositions that include the amorphous esomeprazole salts.

Abstract translation: 本发明涉及奥美拉唑的（ - ）对映异构体或（S） - 对映体的盐的无定形形式，即艾美拉唑。 本发明还涉及制备无定形艾美拉唑盐的方法和包括无定形艾美拉唑盐的药物组合物。

公开(公告)号：US20080312254A1

公开(公告)日：2008-12-18

申请号：US10598370

申请日：2005-02-28

Applicant: Yatendra Kumar ,  Mohan Prasad ,  Mahivir Singh Khanna ,  Seema Ahuja

Inventor： Yatendra Kumar ,  Mohan Prasad ,  Mahivir Singh Khanna ,  Seema Ahuja

IPC: A61K31/501 ,  C07D417/14 ,  A61P25/18

CPC classification number: C07D417/12

Abstract: The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia.

Abstract translation: 本发明涉及制备基本上纯的齐拉西酮的方法。 本发明还涉及齐拉西酮的酸加成盐的制备。 更具体地说，本发明涉及齐拉西酮基本上纯的盐酸盐的制备。 本发明还涉及药物组合物，其包括基本上纯的齐拉西酮或齐拉昔酮盐酸盐以及所述组合物用于治疗精神分裂症的用途。

公开(公告)号：US20060247277A1

公开(公告)日：2006-11-02

申请号：US10546887

申请日：2004-03-01

Applicant: Yatendra Kumar ,  Mahavir Khanna ,  Mohan Prasad

Inventor： Yatendra Kumar ,  Mahavir Khanna ,  Mohan Prasad

IPC: A61K31/4439 ,  C07D403/02

CPC classification number: A61K31/4439

Abstract: This invention relates to polymorphic forms of the S-enantiomer of omeprazole which is S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1Hbenzimidazole. The invention also relates to processes for preparing the polymorphic forms. More particularly, it relates to the preparation of two polymorphic forms of Someprazole, referred to as ‘Form I’ and ‘Form 1’ and pharmaceutical compositions that include the ‘Form I’ and ‘Form II’.

Abstract translation: 本发明涉及奥美拉唑S-对映异构体的多晶型物，其为S-5-甲氧基-2 - [[（4-甲氧基-3,5-二甲基-2-吡啶基） - 甲基]亚磺酰基] -1H-苯并咪唑。 本发明还涉及制备多晶型物的方法。 更具体地说，本发明涉及称为“形式I”和“形式1”的两种多形态的索吡拉唑和包含“I型”和“II型”的药物组合物的制备。

公开(公告)号：US07129365B2

公开(公告)日：2006-10-31

申请号：US10484394

申请日：2002-07-11

Applicant: Yatendra Kumar ,  Mohan Prasad ,  Kaptan Singh ,  Pankaj Sharma

Inventor： Yatendra Kumar ,  Mohan Prasad ,  Kaptan Singh ,  Pankaj Sharma

IPC: C11B3/00

CPC classification number: C07C51/43 ,  C07C51/50 ,  C07C59/64

Abstract: The present invention relates to a cost effective and industrially useful process for the preparation of substantially pure acitretin. More specifically, the present invention relates to the preparation of acitretin of high purity and yield.

Abstract translation: 本发明涉及用于制备基本上纯的阿曲汀的成本有效和工业上有用的方法。 更具体地，本发明涉及高纯度和产率的阿曲酸的制备。

公开(公告)号：US06822119B1

公开(公告)日：2004-11-23

申请号：US10485585

申请日：2004-05-18

Applicant: Yatendra Kumar ,  Mohan Prasad ,  Praveen Kumar Neela ,  Satyananda Misra

Inventor： Yatendra Kumar ,  Mohan Prasad ,  Praveen Kumar Neela ,  Satyananda Misra

IPC: C09B1102

CPC classification number: C07C213/02 ,  C07C217/62

Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of tolterodine and pharmaceutically acceptable salts thereof.

Abstract translation: 本发明涉及用于制备托特罗定及其药学上可接受的盐的成本有效和工业上有利的方法。

公开(公告)号：US06803468B2

公开(公告)日：2004-10-12

申请号：US10363371

申请日：2003-06-20

Applicant: Yatendra Kumar ,  Mohan Prasad ,  Shallendra Kumar Singh

Inventor： Yatendra Kumar ,  Mohan Prasad ,  Shallendra Kumar Singh

IPC: C07C21168

CPC classification number: C07D401/06

Abstract: The present invention relates to an improved and industrially advantageous process for the preparation of N-(5-methylnicotinoyl)-4-hydroxypiperidine of Formula I, as shown in the accompanied drawings. This compound is a key intermediate for the synthesis of rupatadine, a potent dual antagonist of histamine and platelet-activating factor (PAF).